NEUP (Neuphoria Therapeutics) Debt-to-Asset : 0.01 (As of Dec. 2024)

Neuphoria Therapeutics Debt-to-Asset Chart

Neuphoria Therapeutics Annual Data
	Trend	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
Debt-to-Asset		Get a 7-Day Free Trial					0.36	0.02	0.01	0.01	0.01

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.04	0.01	0.01	0.01

Competitive Comparison of Neuphoria Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Neuphoria Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Debt-to-Asset falls into.

Neuphoria Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Neuphoria Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Neuphoria Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics  (NAS:NEUP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Neuphoria Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description